IDSA GUIDELINES Bundle (free trial)

Leishmaniasis

IDSA GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/774306

Contents of this Issue

Navigation

Page 24 of 39

25 Not currently covered by the CDC- sponsored IND protocol • Use undiluted drug. • Consider premedication (eg, with EMLA: lidocaine/prilocaine). • In children, sedation/anesthesia may be required. • Avoid body sites as per heat therapy (see Recs. below). No. In US, would require investigator- sponsored IND protocol. • The capsule formulation of paromomycin is FDA approved for other indications. • Use of the capsules to compound antileishmanial ointment constitutes off- label use. • Local irritation (from MBCL) may lead some patients to discontinue therapy. • Higher response rates noted for infection caused by L. major than L. tropica • See above about paromomycin capsules. • Treatment under expanded-access IND protocol currently is limited to US military health care beneficiaries. Local erythema and/or mild pain are commonly noted. See Recs. 38–39 for some similar drug compounding instructions and the US military point of contact. Yes, cleared for CL indication • Avoid applying over eyelids, tip of nose, lips, mucus membranes, cartilaginous structures, or superficial nerves. • Use topical antibiotics for several days after the heat treatment. • Keloids may be less common than with cryotherapy. Yes. "Grandfathered in" Increased efficacy has been noted if used in combination with IL Sb V . • Avoid applying over eyelids, tip of nose, lips, mucus membranes, cartilaginous structures, or superficial nerves. FDA Approval Comments

Articles in this issue

Archives of this issue

view archives of IDSA GUIDELINES Bundle (free trial) - Leishmaniasis